Dongsung Pharmaceutical Co., Ltd. (002210) Financial Statements

― Followers

Dongsung Pharmaceutical Co., Ltd. Financial Overview

Dongsung Pharmaceutical Co., Ltd.'s market cap is currently ₩133.02B. The company's EPS TTM is $-293.15; its P/E ratio is -4.81; and it has a dividend yield of 0.89%. Dongsung Pharmaceutical Co., Ltd. is scheduled to report earnings on August 14, 2026, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Mar 26	Dec 24	Dec 23	Dec 22	Dec 21
Income Statement
Total Revenue	₩ 87.17B	₩ 88.45B	₩ 88.59B	₩ 93.33B	₩ 84.41B
Gross Profit	₩ 36.36B	₩ 38.88B	₩ 41.37B	₩ 42.06B	₩ 33.54B
Operating Income	₩ -22.87B	₩ -6.59B	₩ 596.40M	₩ -2.04B	₩ -5.30B
EBITDA	₩ -20.73B	₩ -2.05B	₩ 3.42B	₩ 1.53B	₩ -1.73B
Net Income	₩ -25.74B	₩ -7.25B	₩ -2.07B	₩ -2.12B	₩ -4.31B
Balance Sheet
Cash & Short-Term Investments	₩ 3.86B	₩ 3.15B	₩ 6.44B	₩ 4.09B	₩ 5.14B
Total Assets	₩ 168.44B	₩ 151.91B	₩ 114.97B	₩ 107.70B	₩ 104.58B
Total Debt	₩ 64.13B	₩ 52.09B	₩ 43.27B	₩ 37.04B	₩ 29.31B
Net Debt	₩ 60.27B	₩ 48.95B	₩ 36.84B	₩ 32.94B	₩ 26.17B
Total Liabilities	₩ 145.07B	₩ 96.73B	₩ 75.17B	₩ 64.89B	₩ 58.14B
Stockholders' Equity	₩ 23.37B	₩ 55.18B	₩ 39.80B	₩ 42.81B	₩ 46.44B
Cash Flow
Free Cash Flow	₩ -14.16B	₩ -12.41B	₩ -5.22B	₩ -4.53B	₩ -5.08B
Operating Cash Flow	₩ -12.86B	₩ -9.94B	₩ -4.29B	₩ -3.88B	₩ -2.75B
Investing Cash Flow	₩ 3.14B	₩ -6.86B	₩ -927.71M	₩ 638.29M	₩ -9.70B
Financing Cash Flow	₩ 10.46B	₩ 13.51B	₩ 7.57B	₩ 4.24B	₩ 1.23B

Currency in KRW

Dongsung Pharmaceutical Co., Ltd. Earnings and Revenue History

Income Statement >

Dongsung Pharmaceutical Co., Ltd. Debt to Assets

Balance Sheet >

Dongsung Pharmaceutical Co., Ltd. Cash Flow

Cash Flow >

Dongsung Pharmaceutical Co., Ltd. Forecast EPS vs Actual EPS

Earnings >